Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 May;29(5):511–518. doi: 10.1111/j.1365-2125.1990.tb03673.x

Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients.

H F Marlow 1, F L Hine 1, H M Snow 1, H Pouleur 1, M F Rousseau 1
PMCID: PMC1380149  PMID: 2140946

Abstract

1. We examined the relationship between the contractile state of the left ventricle and the plasma concentration of xamoterol in patients with ischaemic heart failure. 2. Identical studies were conducted in 14 middle-aged (all male; mean age 51.3 years, range 42-61) and 10 elderly patients (six male, four female; mean age 67.7 years, range 64-72). 3. Patients received seven cumulative doses (0.0005-0.2 mg kg-1) of xamoterol. After each dose the rate of change of pressure in the left ventricle at a developed pressure of 40 mm Hg and normalised for this pressure, (dP/dt)/DP40, and plasma concentrations of xamoterol were measured. 4. There were dose-related increases in (dP/dt)/DP40. Curves relating changes in (dP/dt)/DP40, expressed as a percent of the maximum observed response, to changes in xamoterol plasma concentrations were constructed for the middle-aged and elderly patients. From these curves the mean effective concentration (EC) value to produce a particular response could be calculated. In the sample sizes studied, the difference between the EC values over a range of responses for the middle-aged and elderly patients did not reach statistical significance, indicating that cardiac responsiveness to xamoterol was similar in the two groups of patients. 5. Plasma concentrations of xamoterol over the range of 39 to 150 ng ml-1 produced positive inotropic responses which varied between 70% and 90% of the maximum observed effect of xamoterol.

Full text

PDF
511

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bastain W., Boyce M. J., Stafford L. E., Morton P. B., Clarke D. A., Marlow H. F. Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur J Clin Pharmacol. 1988;34(5):469–473. doi: 10.1007/BF01046704. [DOI] [PubMed] [Google Scholar]
  2. Benotti J. R., Grossman W., Braunwald E., Davolos D. D., Alousi A. A. Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med. 1978 Dec 21;299(25):1373–1377. doi: 10.1056/NEJM197812212992501. [DOI] [PubMed] [Google Scholar]
  3. Elkayam U., Lejemtel T. H., Mathur M., Ribner H. S., Frishman W. H., Strom J., Sonnenblick E. H. Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol. 1979 Sep;44(3):540–545. doi: 10.1016/0002-9149(79)90409-0. [DOI] [PubMed] [Google Scholar]
  4. Franciosa J. A., Dunkman W. B., Leddy C. L. Hemodynamic effects of vasodilators and long-term response in heart failure. J Am Coll Cardiol. 1984 Jun;3(6):1521–1530. doi: 10.1016/s0735-1097(84)80292-2. [DOI] [PubMed] [Google Scholar]
  5. Franciosa J. A., Weber K. T., Levine T. B., Kinasewitz G. T., Janicki J. S., West J., Henis M. M., Cohn J. N. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J. 1982 Sep;104(3):587–594. doi: 10.1016/0002-8703(82)90231-9. [DOI] [PubMed] [Google Scholar]
  6. Guarnieri T., Filburn C. R., Zitnik G., Roth G. S., Lakatta E. G. Contractile and biochemical correlates of beta-adrenergic stimulation of the aged heart. Am J Physiol. 1980 Oct;239(4):H501–H508. doi: 10.1152/ajpheart.1980.239.4.H501. [DOI] [PubMed] [Google Scholar]
  7. Kendall M. J., Woods K. L., Wilkins M. R., Worthington D. J. Responsiveness to beta-adrenergic receptor stimulation: the effects of age are cardioselective. Br J Clin Pharmacol. 1982 Dec;14(6):821–826. doi: 10.1111/j.1365-2125.1982.tb02043.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lakatta E. G. Alterations in the cardiovascular system that occur in advanced age. Fed Proc. 1979 Feb;38(2):163–167. [PubMed] [Google Scholar]
  9. Lakatta E. G., Gerstenblith G., Angell C. S., Shock N. W., Weisfeldt M. L. Diminished inotropic response of aged myocardium to catecholamines. Circ Res. 1975 Feb;36(2):262–269. doi: 10.1161/01.res.36.2.262. [DOI] [PubMed] [Google Scholar]
  10. Markham R. V., Jr, Corbett J. R., Gilmore A., Pettinger W. A., Firth B. G. Efficacy of prazosin in the management of chronic congestive heart failure: a 6-month randomized, double-blind, placebo-controlled study. Am J Cardiol. 1983 May 1;51(8):1346–1352. doi: 10.1016/0002-9149(83)90310-7. [DOI] [PubMed] [Google Scholar]
  11. Marten T. R., Bourne G. R., Miles G. S., Shuker B., Rankine H. D., Dutka V. N. The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 1984 Sep-Oct;12(5):652–660. [PubMed] [Google Scholar]
  12. Molajo A. O., Bennett D. H. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J. 1985 Jul;54(1):17–21. doi: 10.1136/hrt.54.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ohyagi A., Sasayama S., Nakamura Y., Lee J. D., Kihara Y., Kawai C. Effect of ICI 118,587 on left ventricular function during graded treadmill exercise in conscious dogs. Am J Cardiol. 1984 Nov 1;54(8):1108–1113. doi: 10.1016/s0002-9149(84)80154-x. [DOI] [PubMed] [Google Scholar]
  15. Packer M. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. J Am Coll Cardiol. 1987 Feb;9(2):433–438. doi: 10.1016/s0735-1097(87)80400-x. [DOI] [PubMed] [Google Scholar]
  16. Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
  17. Sato H., Inoue M., Matsuyama T., Ozaki H., Shimazu T., Takeda H., Ishida Y., Kamada T. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation. 1987 Jan;75(1):213–220. doi: 10.1161/01.cir.75.1.213. [DOI] [PubMed] [Google Scholar]
  18. Simonsen S. Haemodynamic effects of ICI 118,587 in cardiomyopathy. Br Heart J. 1984 Jun;51(6):654–657. doi: 10.1136/hrt.51.6.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vigholt-Sørensen E., Faergeman O., Snow H. M. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle. Br Heart J. 1989 Nov;62(5):335–341. doi: 10.1136/hrt.62.5.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Virk S. J., Anfilogoff N. H., Lawson N., Sadler A. M., Smith S. J., Nuttall A., Murray R. G., Littler W. A., Davies M. K. The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure. Eur Heart J. 1989 Mar;10(3):227–234. doi: 10.1093/oxfordjournals.eurheartj.a059470. [DOI] [PubMed] [Google Scholar]
  21. Waller D. G., Webster J., Sykes C. A., Bhalla K. K., Wray R. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group. Eur Heart J. 1989 Nov;10(11):1003–1010. doi: 10.1093/oxfordjournals.eurheartj.a059412. [DOI] [PubMed] [Google Scholar]
  22. Weishaar R. E., Kobylarz-Singer D. C., Steffen R. P., Kaplan H. R. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res. 1987 Oct;61(4):539–547. doi: 10.1161/01.res.61.4.539. [DOI] [PubMed] [Google Scholar]
  23. Wilmshurst P. T., Thompson D. S., Jenkins B. S., Coltart D. J., Webb-Peploe M. M. Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J. 1983 Jan;49(1):77–82. doi: 10.1136/hrt.49.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES